… of target attainment for obese patients with a BMI > 40 kg/m 2 , … obese patients a single dose
of 3 g cefazolin instead of 2 g [Citation79]. Lastly, a microdialysis study in six obese patients (…

… of 30 mg was administered and the effect of obesity could not be separated from the effect of
… -state pharmacokinetic and pharmacodynamic profile of subcutaneous enoxaparin in obese …

… between nonobese and obese patients, and this phenomenon can lead to improper dosing,
often leaving obese patients mistreated for their ailments. Morbidly obese patients are more …

… Conclusion: We developed a pharmacokinetic and pharmacodynamic model of … the
pharmacokinetics of propofol in morbidly obese patients, we investigated the pharmacodynamics …

… that the pharmacokinetics of vecuronium are not altered by obesity. Volumes of distribution,
plasma clearance, distribution, and elimination half-lives were all similar for both obese and …

… and induction of anaesthesia in obese patients based on TBW [46, 47]. However, administration
of propofol to obese patients, particularly morbidly obese patients, according to TBW …

… obese individuals. The distribution of a drug between fat and lean tissues may influence its
pharmacokinetics in obese patients… studies carried out in obese individuals. Adjustment of the …

… As a result, information regarding the impact of obesity on the pharmacokinetics and
pharmacodynamics of the majority of drugs remains limited. While oral drug absorption does not …

… steady-state population pharmacokinetics of meropenem in hospitalized nonobese, obese,
and morbidly obese patients and to evaluate the pharmacodynamics of meropenem over a …

… for obese patients is most often inferred from normal-weight subjects. Pharmacokinetic and
pharmacodynamic … changes in the pharmacokinetics of this drugs in obese normolipaemic, …